Salute e Benessere

Coloplast A/S - Notice of Annual General Meeting 2025

Notice of Annual General Meeting 2025The Annual General Meeting of Coloplast A/S will be held on Thursday, 4 December 2025 at 3:30 pm CET at the premises of Coloplast A/S, Holtedam 3 in Humlebæk (the Aage Louis-Hansen Auditorium), Humlebæk, Denmark.The notice of the Annual General Meeting is enclosed. For further information, please contact Investors and analysts Anders Lonning-Skovgaard Executive Vice President, CFO Tel. +45 4911 1111 Kristine Husted Munk Sr...
Nasdaq GlobeNewswire
11/11/2025

Apollo Cancer Centres Turns Chocolates into Health Reminders with 'Check-Olate'

Eminent breast oncologists at Apollo Cancer Centres stated that when it comes to breast cancer, early detection isn't just important, it's lifesaving. They stressed the fact that ACCs have witnessed firsthand how timely screening and awareness have helped save numerous women through early-stage diagnosis and treatment. Eminent breast oncologists at Apollo Cancer Centres stated that when it comes to breast cancer, early detection isn't just important, it's lifesaving. They stressed the fact…
PR Newswire
11/11/2025

Shilpa Medicare Announces Positive Phase 3 Results for OERIS™ -- A Novel…

This milestone underscores Shilpa's growing leadership in differentiated drug-delivery systems and oncology supportive-care therapeutics, reflecting the company's commitment to advancing patient-centric innovation. This milestone underscores Shilpa's growing leadership indifferentiated drug-delivery systemsandoncology supportive-care therapeutics, reflecting the company's commitment to advancing patient-centric innovation. Study Overview APhase III, multicenter, randomized,...
PR Newswire
11/11/2025

Commit Biologics achieves proof-of-concept for novel Complement Engager platform…

"The positive NHP results represent a major milestone for Commit Biologics. Not only do they validate that the complement system can be used to safely and effectively deplete cells of interest in a highly relevant model they also demonstrate the ability of our platform to generate novel therapeutics with a unique mechanism of action that can be applied across many different indications,"said Mikkel Wandahl Pedersen, Chief Executive Officer of Commit Biologics. "We are pleased to…
PR Newswire
11/11/2025

German health network chooses Sectra to improve diagnostics and reduce risk of…

Xcare Group is a private health network that comprises 12 sites across the Saarland and the Trier/Wittlich regions of Germany. They provide physician practices in the specialties of radiology, nuclear medicine, and radiation therapy, conducting approximately 200,000 radiology exams a year. The contract for Sectra's enterprise imaging solution was signed in the second quarter of Sectra's 2025/2026 fiscal year, and Xcare will utilize the solution's radiology module. Xcare Group is a private...
PR Newswire
11/11/2025

RefluxStop® takes center stage at 2025 European Foregut Society meeting

The RefluxStop Symposium, 'RefluxStop for GERD: Excellent long-term outcomes' drew a full house of around 100 doctors to hear about the device's rapidly evolving excellent long-term and real-world outcomes data. The distinguished panel of RefluxStop experts included: Prof. Sebastian Schoppmann, Dr. med. Yves Borbély, Dr. med. Moustafa Elshafei and Dr. med. Thorsten Lehmann. They provided an in-depth perspective on RefluxStop® to treat reflux disease, followed by constructive discussions with a…
PR Newswire
11/11/2025

Ariceum Therapeutics Doses First Patient in SANTANA-225 Phase 1/2 Clinical Trial…

225Ac-SSO110 has received U.S. FDA Orphan Drug DesignationInitial safety data from SANTANA-225 in ES-SCLC and MCC expected in 2026Potential to address a broad range of neuroendocrine cancersBERLIN, Nov.11, 2025(GLOBE NEWSWIRE) -- Ariceum Therapeutics (Ariceum), a targeted radiotherapeutics company dedicated to setting new standards in cancer care, today announced that the first patient has been dosed in the SANTANA-225 Phase 1/2 study of 225Ac-SSO110 for the treatment of...
Nasdaq GlobeNewswire
11/11/2025

Natura's corporate simplification progresses, while profitability was impacted…

The revenue decline, driven by consumption constraints in Brazil and temporary operational challenges in Argentina and Mexico — three markets that together represent around 85% of the business — resulted in lower expense dilution. As a result, the recurring EBITDA margin in Latin America was 11.7% (-360 bps). Gross margin remained healthy across the region. The revenue decline, driven by consumption constraints inBraziland temporary operational challenges inArgentinaandMexico— three...
PR Newswire
11/11/2025

Onward Therapeutics Completes Share Exchange and Establishes Global Headquarters…

Over the past six years, Onward has built a robust pipeline of four innovative programs targeting both solid and hematologic tumors, through in-licensing, acquisition, and internal discovery. The group reorganization was designed to align Onward's corporate structure with Taiwan's dynamic biotechnology capital market and to support the company's long-term growth plans, including future fundraising and potential public listing. Over the past six years, Onward has built a robust pipeline of…
PR Newswire
11/11/2025

Oropharyngeal Cancer Market to Register Steady CAGR Throughout Forecast Period…

Oropharyngeal Cancer Market Summary Oropharyngeal Cancer Market Summary Discover the oropharyngeal cancer new treatment @New Treatments for Oropharyngeal Cancer Key Factors Driving the Growth of the Oropharyngeal Cancer Market Rising Incidence of HPV+ Oropharyngeal Cancer HPV-driven OPSCC has increased sharply in many regions, shifting the disease burden and creating demand for new diagnostics and specialized treatments. Role of PD-1/PD-L1 Inhibitors PD-1...
PR Newswire
10/11/2025

Oculis Reports Q3 2025 Financial Results and Provides Company Update

Oculis accelerates its portfolio development with Privosegtor moving into the PIONEER pivotal program in Acute Optic Neuritis (AON) andNon-arteritic Anterior Ischemic Optic Neuropathy (NAION) following positive FDA meeting OCS-01 DIAMOND Phase 3 trials in diabetic macular edema (DME) remain on track for topline results expected in Q2 2026 Licaminlimab PREDICT-1 registrational trial, thefirst genotype-based trial to drive precision medicine in dry eye disease (DED), expected to...
Nasdaq GlobeNewswire
10/11/2025

Bavarian Nordic Announces Major Shareholder Notification from Morgan Stanley

COPENHAGEN, Denmark, November 10, 2025– Pursuant to section 30 of the Danish Capital Markets Act, Bavarian Nordic A/S hereby announces that the Company has received notification from Morgan Stanley that they hold 4,94% of the shares and voting rights in Bavarian Nordic A/S as of November 4, 2025.About Bavarian NordicBavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox...
Nasdaq GlobeNewswire
10/11/2025

Ascend Unveils Proprietary Enhancers That Significantly Improve AAV Yields…

Developed through a collaborative research effort, two enhancers have now been tested at multiple scales in HEK293 cells using Ascend's EpyQ® two-plasmid AAV Production System and a commercially available 3-plasmid system, with no negative effects on quality parameters such as vg/cap ratio or mispackaged DNA being observed. Enhancer activity was further confirmed using customer plasmids. Developed through a collaborative research effort, two enhancers have now been tested at multiple scales…
PR Newswire
10/11/2025

Idorsia’s aprocitentan improved key prognostic indicators in patients with…

New analysis from landmark Phase 3 PRECISION trial published in theJournal of Hypertensionhighlights aprocitentan led to improvements in dipping pattern and BP loadFindings reinforce the role of aprocitentan’s novel endothelin pathway mechanism in addressing significant medical need in difficult-to-control hypertensionAllschwil, Switzerland – November 10, 2025Idorsia Ltd (SIX: IDIA) announced the publication of a new analysis from the landmark Phase 3 PRECISION study in the...
Nasdaq GlobeNewswire
10/11/2025

NTG Nordic Transport Group publishes interim report for Q3 2025

Company announcement no. 10 – 25 10 November 2025 NTG Nordic Transport Group publishes interim report for Q3 2025The interim report for Q3 2025 is enclosed.In connection with publication of the results for Q3 2025, a conference call will be hosted on 11 November 2025 at 10:00 AM CET.The conference call will be held in English and can be followed live via NTG’s website ; investor.ntg.com. Additional information For additional information, please contact: Investor relations...
Nasdaq GlobeNewswire
10/11/2025

Patient Monitoring Devices Market to be Worth $118.21 Billion by 2033 at CAGR of…

Request a free sample copy of this report: Patient Monitoring Devices Market Request a free sample copy of this report:Patient Monitoring Devices Market Innovation is a key driver, accelerating with advancements in AI-enabled analytics, cellular connectivity, and device interoperability, pushing companies toward smart, patient-friendly solutions that offer continuous, reliable data and predictive insights for proactive care models. A notable example is Roche'sJuly 2024CE mark...
PR Newswire
10/11/2025

Genmab Provides Certain Information Disclosed in Connection with Proposed…

Media ReleaseCOPENHAGEN, Denmark; November 10, 2025Genmab A/S (“Genmab”) announced on November 10, 2025, that it and its wholly owned subsidiary Genmab Finance LLC intend to offer, subject to market and other conditions, $1.5 billion of senior secured notes due 2032 (the “Secured Notes”) and $1.0 billion of senior unsecured notes due 2033 (the “Unsecured Notes,” and together with the Secured Notes, the “Notes”).Genmab also launched the syndication of a new $2.0 billion senior...
Nasdaq GlobeNewswire
10/11/2025

Capnography Equipment Market worth $0.67 billion by 2030 with 4.6% CAGR |…

Browse in-depth TOC on "Capnography Equipment Market" Browse in-depth TOC on "Capnography Equipment Market" 421 - Tables 59 - Figures 320 - Pages By product,Capnography accessories and disposables lead the capnography equipment market, capturing the largest share due to their essential role in ensuring accurate and continuous CO2 monitoring in clinical settings. Items such as nasal and oral cannulas, sampling lines, airway adapters, and filters are crucial for both...
PR Newswire
10/11/2025

Novartis opens new radioligand therapy manufacturing facility in California as…

Carlsbad location is company’s third US-based radioligand therapy (RLT) manufacturing site New site expands manufacturing footprint to meet future demand; ensures continued on-time delivery rate of >99.9% to patients across western US, Alaska and HawaiiFirst to have delivered at scale, Novartis fortifies leadership in RLT innovation and infrastructure with California facility, additional plans for Florida and TexasBasel, November 10, 2025– Novartis, a leading...
Nasdaq GlobeNewswire
10/11/2025

Novo Nordisk's Wegovy® (semaglutide 2.4 mg) was associated with liver…

This post hoc analysis of the ESSENCE trial evaluated the first 800 randomized patients at 72 weeks. Histological and non-invasive testing (NIT)­–related treatment responses were evaluated according to specific weight loss thresholds (≤2%, ≤5%, ≤7%, >7%).1 Steatohepatitis-related NITs improved in all groups receiving semaglutide 2.4 mg, with the greatest treatment effect observed for alanine aminotransaminase (ALT) in patients with weight loss of ≤7%. In this subgroup, patients receiving…
PR Newswire
10/11/2025

Halia Therapeutics to Present Groundbreaking Data on Novel Allosteric NEK7…

- Preclinical data reveal potential applications in hemolytic anemias and obesity-induced inflammatory anemia - - Preclinical data reveal potential applications in hemolytic anemias and obesity-induced inflammatory anemia - LEHI, Utah , Nov. 10, 2025 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical company developing first-in-class anti-inflammatory therapies, today announced six poster presentations and one oral presentation at the 67 thAmerican Society of...
PR Newswire
10/11/2025

Avid Bioservices appoints Dave Stewart as Chief Technology and Transformation…

The addition of this role represents an important step in CEO Kenneth Bilenberg's strategy to position Avid for continued expansion – and to be the easiest external partner to work with: reliable, predictable, and proactive at every stage. The addition of this role represents an important step in CEOKenneth Bilenberg'sstrategy to position Avid for continued expansion – and to be the easiest external partner to work with: reliable, predictable, and proactive at every stage. "Avid has...
PR Newswire
10/11/2025

Cellex Symposium 2025 Brings Together International Experts to Discuss the…

Driving Innovation and Investment in the Next Era of Immune Cell Therapies Driving Innovation and Investment in the Next Era of Immune Cell Therapies The opening session focused on innovation, funding, and the next generation of immune cell therapy platforms. Dr. Karl Nägler, Sofinnova Partners, provided an insightful overview of venture capital opportunities and challenges in CGT investments, whileKenneth Lockediscussed the use of cell-derived nanoparticles to overcome key barriers...
PR Newswire
10/11/2025

Brainomix Recognized in Global Health Tech Competition for Its Innovative…

"We're honored to be recognized by the American Heart Association for our Brainomix 360 Stroke technology," said Michalis Papadakis, Ph.D., Chief Executive Officer and Co-Founder of Brainomix. "This award affirms our commitment to transforming cardiovascular and stroke care through innovation and scientific rigor." "We're honored to be recognized by the American Heart Association for our Brainomix 360 Stroke technology," saidMichalis Papadakis, Ph.D., Chief…
PR Newswire
10/11/2025
Altri  Comunicati